PubMed Health⌕ Search

PubMed · 6407451

[Secondary angina pectoris. Generalities].

Abstract

Secondary angina pectoris (AP) resulting from an increase in myocardial oxygen demands not satisfied by increased coronary flow because of severe and usually multiple atherosclerotic lesions, contrasts with primary AP due to decreased coronary flow usually due to coronary spasm. Secondary AP corresponds clinically to Heberden's common AP induced by conditions which increase the metabolic demands of the myocardium: tachycardia, increased parietal tension and myocardial contractility, prolongation of the ejection period. In practice, secondary AP is preceded by an elevation in the rate-pressure product. Factors which give rise to tachycardia, increased after and preload, increased inotropism and ventricular ejection may cause secondary AP at a critical level of fixed reduction of the coronary vascular bed. Mixed AP is due to the association of fixed anatomical lesions and coronary spasm in variable proportions. The physiopathological principles should be born in mind when taking therapeutic decisions.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

P Puech. 1983. [Secondary angina pectoris. Generalities].. https://pubmed.ncbi.nlm.nih.gov/6407451/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Effect of a hypoglycemic agent on ischemic preconditioning in patients with type 2 diabetes and stable angina pectoris.

OBJECTIVE: Ischemic preconditioning is an increased tolerance to myocardial ischemia during the second of two consecutive exercise tests. ATP-sensitive K(+) channel blockers, such as glinides and sulfonylurea drugs, can induce loss of ischemic preconditioning. This study aimed to investigate the effects of repaglinide, a hypoglycemic agent with an affinity for myocardial ATP-sensitive K (+)channels, on the results of consecutive exercise tests in patients with diabetes and multivessel coronary artery disease. METHODS: Forty-two patients with type 2 diabetes and chronic stable angina pectoris, and two-vessel or three-vessel disease participated in this study. The patients underwent two consecutive treadmill exercise tests (phase 1). On the day after these exercise tests, 2 mg of oral repaglinide was given to the patients. One week later, two exercise tests were repeated consecutively (phase 2). RESULTS: All patients achieved 1.0-mm ST-segment depression during the four exercise tests (T1, T2, T3, and T4). In phase 2, seven patients improved in time to onset of 1.0-mm ST-segment depression. The worsening of the time to onset of 1.0-mm ST-segment depression in phase 2 demonstrated ischemic preconditioning block in 83.3% of patients (P=0.0001). Even the postexercise electrocardiographic parameters (ST-segment depression morphology and magnitude and arrhythmias) were significantly different between the groups with and without pharmacologic ischemic preconditioning block (P=0.031). CONCLUSIONS: Repaglinide, an oral hypoglycemic agent with ATP-sensitive K(+) channel-blocker activity, eliminated the myocardial ischemic preconditioning in patients with coronary disease and diabetes.

Angina Pectoris↗